Yang Wang

Prior to joining Cao Pharmaceuticals, she had over twenty years of experience in CPT (camptothecin) related drug development as a Research Scientist at the Stehlin Foundation for Cancer Research. At Cao Pharmaceuticals she oversees both the pre-clinical testing and formulation development of the pipeline drugs, and the clinical pharmacokinetics, pharmacodynamics, and biomodeling studies of the phase I clinical trial of CZ48, a camptothecin derivative.